A Florida-based company called MicroNeb and a privately-held biopharma company called US Precision Medicine (USPM) say that they have signed a memorandum of understanding allowing USPM to use MicroNeb nebulizer technology for delivery of an inhaled cancer drug. The MicroNeb web site currently does not provide images, data, or specific details related to any handheld nebulization system other than the names “HALO – NebResQ” and “VIGIL.”
In the press release, USPM CEO Frederick Fey lists benefits of the MicroNeb technology for delivery of the drug to the lung, most of which are applicable to inhalation in general. One specific claim that he lists is “Precision Dosing: The design feature of the VIGIL delivers exact doses, crucial for maintaining optimal therapeutic levels while avoiding toxicity.”
On the MicroNeb LinkedIn page, the company says “Our proprietary technology allows for high absorption rates and smokeless exhalation of atomized liquids. Completely portable and battery-powered, the device records patient usage data and has built-in tamper-resistant safeguards. The PND provides a heatless, targeted, and user-friendly delivery system that will transform how individuals consume medicines and supplements.”
The page also says that MicroNeb has a “specialization in creating inhalable formulations of isolated nutrients, herbal extracts, and other wellness bioactives” and that it uses “FDA-approved methods.” Company CEO/President Brian M. Artze is the only employee of MicroNeb listed on LinkedIn.
The MicroNeb web site claims that “Our devices deliver Naloxone rapidly and effectively, ensuring fast absorption into the bloodstream” and claims in a section titled “Case Studies” that “MicroNeb’s PNDs, equipped with naloxone, provide immediate overdose reversal, crucial in saving lives amid the opioid crisis.” The site also claims delivery of “instant pain relief and essential medications, transforming emergency care in combat zones” and delivery of nintendanib by “Leveraging liposome nanoparticles” for the treatment of IPF as “case studies.”
Artze commented, “With our sophisticated inhalation technology and formulation expertise, we are transforming the delivery of pharmaceuticals and wellness products. Our dedication to quality and innovation compels us to develop cutting-edge solutions with a team committed to improving patient outcomes. Our personal nebulizing devices (PNDs) represent the future of precise medication delivery, boosting efficacy in numerous medical applications. We are excited to support US Precision Medicine’s mission to introduce their new, promising cancer drug candidate and look forward to progressing through the trials together.”
Read the US Precision Medicine press release.
